119 related articles for article (PubMed ID: 37294724)
21. Relationship Between NT-proBNP Levels and Left Ventricular Ejection Fraction in Patients with Unstable Angina and Diabetes Mellitus and Preserved LVEF.
Gao X; Liu R; Wang P; Wang W; Zhao HQ
Int Heart J; 2022; 63(5):821-827. PubMed ID: 36184543
[TBL] [Abstract][Full Text] [Related]
22. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
Solomon SD; Vaduganathan M; Claggett BL; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Belohlavek J; Chiang CE; Willem Borleffs CJ; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Kerr Saraiva JF; Tereschenko SN; Thierer J; Vardeny O; Verma S; Vinh PN; Wilderäng U; Zaozerska N; Lindholm D; Petersson M; McMurray JJV
JACC Heart Fail; 2022 Mar; 10(3):184-197. PubMed ID: 35241246
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
24. Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
Ohte N; Tanaka A; Kitada S; Yamada T; Eguchi K; Teragawa H; Takeishi Y; Kodama K; Seo Y; Node K;
J Cardiol; 2023 Jun; 81(6):508-512. PubMed ID: 36481298
[TBL] [Abstract][Full Text] [Related]
25. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Myhre PL; Vaduganathan M; Claggett BL; Miao ZM; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JACC Heart Fail; 2022 Dec; 10(12):902-913. PubMed ID: 36114137
[TBL] [Abstract][Full Text] [Related]
26. Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes.
Dencker M; Stagmo M; Dorkhan M
Vasc Health Risk Manag; 2010 Jun; 6():373-82. PubMed ID: 20539839
[TBL] [Abstract][Full Text] [Related]
27. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.
Costello-Boerrigter LC; Boerrigter G; Redfield MM; Rodeheffer RJ; Urban LH; Mahoney DW; Jacobsen SJ; Heublein DM; Burnett JC
J Am Coll Cardiol; 2006 Jan; 47(2):345-53. PubMed ID: 16412859
[TBL] [Abstract][Full Text] [Related]
28. Biochemical diagnosis of impaired left ventricular ejection fraction--comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP).
Mueller T; Gegenhuber A; Poelz W; Haltmayer M
Clin Chem Lab Med; 2004 Feb; 42(2):159-63. PubMed ID: 15061354
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
[TBL] [Abstract][Full Text] [Related]
30. Analysis of combined detection of N-terminal pro-B-type natriuretic peptide and left ventricular ejection fraction in heart function in patients with acute CO poisoning.
Liu SD; Shen Q; Lv C; Zhang P; Yu H; Yang L; Wu L
Am J Emerg Med; 2014 Oct; 32(10):1212-4. PubMed ID: 25151325
[TBL] [Abstract][Full Text] [Related]
31. Assessment of global longitudinal strain and plasma natriuretic peptide in patients with asymptomatic left ventricular dysfunction.
Ulziisaikhan G; Khurelbaatar MU; Khorloo C; Sodovsuren N; Khasag A; Unurjargal T
Kardiologiia; 2021 Oct; 61(10):53-60. PubMed ID: 34763639
[TBL] [Abstract][Full Text] [Related]
32. Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction.
Gergei I; Krämer BK; Scharnagl H; Stojakovic T; März W
Peptides; 2019 Jan; 111():112-117. PubMed ID: 29684593
[TBL] [Abstract][Full Text] [Related]
33. Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K; Imai T; Tanaka A; Dohi K; Shiina K; Yamada T; Kida K; Eguchi K; Teragawa H; Takeishi Y; Ohte N; Yamada H; Sata M; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):186. PubMed ID: 34521417
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population.
Groenning BA; Raymond I; Hildebrandt PR; Nilsson JC; Baumann M; Pedersen F
Heart; 2004 Mar; 90(3):297-303. PubMed ID: 14966052
[TBL] [Abstract][Full Text] [Related]
35. Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study.
Nah EH; Kim SY; Cho S; Kim S; Cho HI
BMJ Open; 2019 Apr; 9(4):e026030. PubMed ID: 31005928
[TBL] [Abstract][Full Text] [Related]
36. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
[TBL] [Abstract][Full Text] [Related]
37. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials.
Werhahn SM; Becker C; Mende M; Haarmann H; Nolte K; Laufs U; Zeynalova S; Löffler M; Dagres N; Husser D; Dörr M; Gross S; Felix SB; Petersmann A; Herrmann-Lingen C; Binder L; Scherer M; Hasenfuß G; Pieske B; Edelmann F; Wachter R
ESC Heart Fail; 2022 Feb; 9(1):100-109. PubMed ID: 34850596
[TBL] [Abstract][Full Text] [Related]
38. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis.
David S; Kümpers P; Seidler V; Biertz F; Haller H; Fliser D
Nephrol Dial Transplant; 2008 Apr; 23(4):1370-7. PubMed ID: 18089624
[TBL] [Abstract][Full Text] [Related]
40. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients.
Racek J; Králová H; Trefil L; Rajdl D; Eiselt J
Nephron Clin Pract; 2006; 103(4):c162-72. PubMed ID: 16645318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
